This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by García-Calvo, G.
Right arrow Articles by Soriano, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by García-Calvo, G.
Right arrow Articles by Soriano, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1876-1878, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1876-1878.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Antibacterial Properties of Gemifloxacin and Trovafloxacin in Urine Ex Vivo: Phase I Study

Gloria García-Calvo,1 Araceli Parra,1 Lorenzo Aguilar,2 Carmen Ponte,1 María J. Giménez,2 Antonio Carcas,3 Martina Kinzig-Schippers,4 and Francisco Soriano1,*

Medical Microbiology Department, Fundación Jiménez Díaz,1 Medical Department, GlaxoSmithKline, Tres Cantos,2 and Clinical Pharmacology Unit, Universidad Autónoma,3 Madrid, Spain, and IBMP---Institute of Pharmaceutical Research, Nürnberg-Heroldsberg, Germany4

Received 15 June 2000/Returned for modification 1 February 2001/Accepted 8 March 2001

Urine bactericidal titers (UBTs) against Escherichia coli ATCC 25922 and Staphylococcus saprophyticus ATCC 1970 were determined after the administration of single oral doses of gemifloxacin at 320 mg and trovafloxacin at 200 mg to healthy volunteers. Gemifloxacin presented significantly lower experimental versus mathematically predicted UBTs over 72 h, due to the effect of urine on the susceptibility of the E. coli strain. Experimental UBTs were significantly higher for gemifloxacin than trovafloxacin against both strains over 72 h.

* Corresponding author. Mailing address: Medical Microbiology Department, Fundación Jiménez Díaz, Av. Reyes Católicos, 2, 28040 Madrid, Spain. Phone: 34-91-5447387. Fax: 34-91-5494764. E-mail: fsoriano{at}fjd.es.

Antimicrobial Agents and Chemotherapy, June 2001, p. 1876-1878, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1876-1878.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.




Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»